First Korean Clinical Outcomes Of A New Refrative Lenticular Extraction Procedure Using The Schwind Atos Laser Flatform – Smartsight.
Published 2023 - 41st Congress of the ESCRS
Reference: PO0951 | Type: Free paper | DOI: 10.82333/mvkt-1b06
Authors: Hyosung Yoon* 1 , Dong-ju Yeom 1
1Gangnam smile eye clinic,Seoul,Korea, Republic Of
Purpose
To evaluate refractive and visual outcomes of small incision Guided Human-cornea Treatment (SmartSight® , SCHWIND eye-tech-solutions, Kleinostheim, Germany) in the treatment of myopic astigmatism with a new femtosecond laser system.
Setting
Gangnam smile eye clinic, Seoul, Korea
Methods
This retrospective, observational case series include 230 eyes of 117 patients who underwent SmartSight to correct myopic astigmatism and completes at least 3 months follow-up. All procedures were performed by the same surgeon using the SCHWIND ATOS® second laser. The patients were evaluated preoperatively and followed up at least 3 months after the operation. Refractive value, visual acuity, corneal higher-order aberrations (the RMS value of total HOA, SA, and coma) were measured at each visit.
Results
All patients underwent uneventful SmartSight lenticule extraction. Preoperatively, mean spherical equivalent was –4.61 ± 1.83 diopters(D) and, astigmatism was –1.04 ± 0.85D. The RMS values of total HOA, SA, and coma for 6mm pupils were 0.32± 0.06, 0.17 ± 0.05, and 0.14 ± 0.02 µm. The post operative spherical equivalent correction within ±0.50D was achieved in 226 eyes (98%) and cylindrical correction within ±0.50D in 228 eyes (99%) at 3 months after the operation. Post operative UDVA was 20/20 in 225 eyes (98%) at 3 months and no eye had lost two or more snellen lines of corrected distance visual acuity. The RMS values of total HOA, SA, and coma were 0.38± 0.07, 0.21 ± 0.05, and 0.15 ± 0.04 µm at 3 months after operation.
Conclusions
Myopic astigmatism correction with a new femtoseconlaser platform (Schwind Atos) provides good results for efficacy, safety, visual outcomes and corneal higher-order aberrations at the 3 months of follow up.